Tonghua Dongbao Liraglutide Injection Accepts GMP On-site Audit by the Egyptian Ministry of Health
March 3, 2025
Source: drugdu
29
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. and its partner Sinovac Biotech Co., Ltd. (hereinafter referred to as "Sinovac") jointly launched the overseas product Liraglutide Injection, which received the GMP on-site audit by the Egyptian Ministry of Health. The audit was conducted at the company's production base. The company and Sinovac Biotech collaborated efficiently and closely cooperated with the on-site inspection of the Egyptian Ministry of Health, which is currently progressing smoothly. Liraglutide, as a human glucagon-like peptide-1 (GLP-1) analog, can activate human GLP-1 receptors and promote pancreatic insulin secretion. In addition to effectively controlling blood sugar, it can also protect cardiovascular and reduce weight. The product has significant efficacy and high safety, and is widely recognized worldwide.
https://finance.eastmoney.com/a/202502283332960051.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- CEO of radiotherapy giant resigns March 4, 2025
- Seven new rare disease drugs have been given priority review, from companies such as Johnson&Johnson, Rongchang Biotech, and Hansen Pharmaceuticals March 4, 2025
- Hengrui steps down as the ‘top pharmaceutical expert’, and BeiGene ascends to the top for the first time! How can Hengrui break through? March 4, 2025
- Chengdu Pioneer disclosed its shareholder reduction plan; Amycritin Injection Approved for Clinical Use in China | Medical Early Reference March 4, 2025
- 164 measles cases have been reported in the United States March 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
